Importer of Controlled Substances Application: AndersonBrecon Inc. dba PCI of Illinois, 27248-27249 [2020-09707]
Download as PDF
<![CDATA[
27248
Federal Register / Vol. 85, No. 89 / Thursday, May 7, 2020 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–643]
Importer of Controlled Substances
Application: Almac Clinical Services
Incorp. (ACSI)
ACTION:
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
DEPARTMENT OF JUSTICE
In
accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2020, Almac
Clinical Services Incorp. (ACSI), 25
Fretz Road, Souderton, Pennsylvania
18964, applied to be registered as an
importer of the following basic class(es)
of a controlled substance:
Bulk Manufacturer of Controlled
Substances Application: Alcami
Wisconsin Corporation
SUPPLEMENTARY INFORMATION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 8, 2020. Such persons
may also file a written request for a
hearing on the application on or before
June 8, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
Controlled substance
Drug
code
Schedule
Noroxymorphone ......
9668
II
The company plans to import the
listed controlled substance in dosage
form to conduct clinical trials.
William T. McDermott,
Assistant Administrator.
Drug Enforcement Administration
[Docket No. DEA–639]
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 6, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 13, 2020, Alcami
Wisconsin Corporation, W130N10497
Washington Drive, Germantown,
Wisconsin 53022–4448, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substances:
SUPPLEMENTARY INFORMATION:
[FR Doc. 2020–09701 Filed 5–6–20; 8:45 am]
BILLING CODE 4410–09–P
Controlled substance
Drug code
Marihuana Extract ...........................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Thebaine ..........................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
The company plans to provide bulk
active pharmaceutical ingredient to
support clinical trials. In reference to
drug codes 7350 Marihuana extract,
7360 Marihuana, and 7370
Tetrahydrocannabinols, the company
plans to manufacture these substances
synthetically. No other activities for
these drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
William T. McDermott,
Assistant Administrator.
DATES:
[FR Doc. 2020–09702 Filed 5–6–20; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 4410–09–P
VerDate Sep<11>2014
16:45 May 06, 2020
Jkt 250001
Drug Enforcement Administration
[Docket No. DEA–641]
Importer of Controlled Substances
Application: AndersonBrecon Inc. dba
PCI of Illinois
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 8, 2020. Such persons
may also file a written request for a
hearing on the application on or before
June 8, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
7350
7360
7370
7431
9333
9737
Schedule
I
I
I
I
II
II
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on March 20, 2020,
AndersonBrecon Inc. dba PCI of Illinois,
5775 Logistics Parkway, Rockford,
Illinois 61109–3608, applied to be
registered as an importer of the
following basic class(es) of a controlled
substance:
SUPPLEMENTARY INFORMATION:
E:\FR\FM\07MYN1.SGM
07MYN1
Federal Register / Vol. 85, No. 89 / Thursday, May 7, 2020 / Notices
Controlled substance
Drug
code
Schedule
Tetrahydrocannabinols
7370
I
The company plans to import the
listed controlled substance for clinical
trial only. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of Food
and Drug Administration-approved or
non-approved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–09707 Filed 5–6–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice Requesting Public Comment on
the Proposed Methodology To
Distribute Outcome Payments to
States for the Unemployment
Insurance (UI) Reemployment Services
and Eligibility Assessments (RESEA)
Program in Accordance With Title III,
Section 306(f)(2) of the Social Security
Act (SSA)
Employment and Training
Administration (ETA), U.S. Department
of Labor (Department).
ACTION: Request for public comment.
AGENCY:
The Department is seeking
public comment on the proposed
methodology to distribute RESEA
outcome payments to states each fiscal
year (FY) after FY 2020 as required by
Section 306(f)(2), SSA.
DATES: Submit written comments to the
office listed in the addresses section
below on or before June 8, 2020.
ADDRESSES: Questions on this notice
and responsive comments related to the
RESEA outcome payments allocation
can be submitted to the U.S. Department
of Labor, Employment and Training
Administration, Office of
Unemployment Insurance, 200
Constitution Avenue NW, Room S–
4524, Washington, DC 20210, Attention:
Lawrence Burns, or by email at DOLETA-UI-FRN@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Lawrence Burns, Division of
Unemployment Insurance Operations, at
202 693–3141 (this is not a toll-free
number), TTY 1–877–889–5627 (this is
not a toll-free number), or by email at
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:45 May 06, 2020
Jkt 250001
Burns.Lawrence@dol.gov. The
Department will respond to comments
directly as necessary.
SUPPLEMENTARY INFORMATION: ETA
proposes a three-step approach to
determine whether a state is eligible for
RESEA Outcome Payments. The
proposed approach reflects RESEA’s
statutory purpose, as defined in Section
306(b)(1), SSA, to improve employment
outcomes of individuals that receive
unemployment compensation (UC) and
to reduce the average duration of receipt
of such compensation through
employment. The three-step approach
includes:
1. Evaluation of state reemployment
performance using the RESEA program
to determine if a state met or exceeded
the target for the Reemployment Rate in
the 2nd Quarter After Program Exit for
RESEA participants performance
measure;
2. Evaluation of the state’s Average UI
duration to determine if the state
demonstrated a decrease in its average
UI duration as a result of the RESEA
services provided to UI claimants; and
3. Award allocation.
I. Introduction
The federal-state UI program is a
required partner in the comprehensive,
integrated workforce system.
Individuals who have lost employment
through no fault of their own and have
earned sufficient wage credits, may
receive UI benefits if they meet initial
and continuing eligibility requirements.
Beginning in 2005, the Department and
participating state workforce agencies
have been addressing the individual
reemployment needs of UI claimants
and working to prevent and detect UI
improper payments through the
voluntary UI Reemployment and
Eligibility Assessment (REA) program.
Beginning in FY 2015, the voluntary
RESEA program replaced the REA
program. On February 9, 2018, the
President signed the Bipartisan Budget
Act of 2018 (Pub. L. 115–123) (BBA),
which included amendments to the SSA
creating a permanent authorization for
the RESEA program. In FY 2019, a total
of 50 states and jurisdictions operated a
RESEA program.
The primary goals for the RESEA
program are to: Improve employment
outcomes for individuals that receive
UC and to reduce average duration of
receipt of UC through employment;
strengthen program integrity and reduce
improper payments; promote alignment
with the broader vision of the Workforce
Innovation and Opportunity Act
(WIOA)—increasing program integration
and service delivery for job seekers; and
establish RESEA as an entry point to
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
27249
other workforce system partner
programs for individuals receiving UC.
II. Background
The RESEA provisions are contained
in Section 30206 of the BBA, enacting
Section 306 of the SSA. In addition to
program requirements, Section 306 of
the SSA also contains provisions for the
funding of the RESEA program. The law
specifies three uses and designates the
proportion of annual appropriations to
be assigned to these uses: (1) Base
funding for states to operate the RESEA
program (84 percent to 89 percent
depending on the year); (2) outcome
payments designed to reward states
meeting or exceeding certain criteria (10
percent to 15 percent of the
appropriation depending on the year);
and (3) up to one percent for the
Secretary of Labor to use for research
and technical assistance to states.
Additionally, the law requires the
Department to develop a methodology
to allocate and distribute base funding
and outcome payments to states
beginning in FY 2021.
In August 2019, ETA published a
Notice in the Federal Register to inform
states of the methodology to allocate
base funding to states for the RESEA
program. Details regarding the RESEA
base formula allocation methodology
can be found at: https://
www.federalregister.gov/documents/
2019/08/08/2019-16988/allocatinggrants-to-states-for-reemploymentservices-and-eligibility-assessmentsresea-in. The present Notice proposes
the methodology to distribute RESEA
outcome payments to states.
Section 306(f)(2)(A), SSA requires
ETA to make ‘‘outcome payments’’ to
states that meet or exceed the outcome
goals for reducing the average duration
of receipt of UC by improving
employment outcomes. The law
specifically states:
‘‘IN GENERAL.—Of the amounts made
available for grants under this section for
each fiscal year after 2020, the Secretary shall
reserve a percentage equal to the outcome
reservation percentage 1 for such fiscal year
for outcome payments to increase the amount
otherwise awarded to a State under
paragraph (1). Such outcome payments shall
be paid to States conducting reemployment
services and eligibility assessments under
this section that, during the previous fiscal
year, met or exceeded the outcome goals
provided in subsection (b)(1) related to
reducing the average duration of receipt of
unemployment compensation by improving
employment outcomes’’.
1 Section 306(f)(2)(B), SSA defines the ‘‘outcome
reservation percentage’’ as 10 percent for fiscal
years 2021 through 2026 and 15 percent for fiscal
years thereafter.
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 85, Number 89 (Thursday, May 7, 2020)]
[Notices]
[Pages 27248-27249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09707]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-641]
Importer of Controlled Substances Application: AndersonBrecon
Inc. dba PCI of Illinois
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before June 8, 2020.
Such persons may also file a written request for a hearing on the
application on or before June 8, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on March 20, 2020, AndersonBrecon Inc. dba PCI of
Illinois, 5775 Logistics Parkway, Rockford, Illinois 61109-3608,
applied to be registered as an importer of the following basic
class(es) of a controlled substance:
[[Page 27249]]
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols................. 7370 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance for
clinical trial only. Approval of permit applications will occur only
when the registrant's business activity is consistent with what is
authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to
the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-09707 Filed 5-6-20; 8:45 am]
BILLING CODE 4410-09-P
